1. Home
  2. REPL vs OFIX Comparison

REPL vs OFIX Comparison

Compare REPL & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • OFIX
  • Stock Information
  • Founded
  • REPL 2015
  • OFIX 1987
  • Country
  • REPL United States
  • OFIX United States
  • Employees
  • REPL N/A
  • OFIX N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • OFIX Medical/Dental Instruments
  • Sector
  • REPL Health Care
  • OFIX Health Care
  • Exchange
  • REPL Nasdaq
  • OFIX Nasdaq
  • Market Cap
  • REPL 547.0M
  • OFIX 564.4M
  • IPO Year
  • REPL 2018
  • OFIX N/A
  • Fundamental
  • Price
  • REPL $9.73
  • OFIX $15.44
  • Analyst Decision
  • REPL Buy
  • OFIX Strong Buy
  • Analyst Count
  • REPL 9
  • OFIX 6
  • Target Price
  • REPL $10.88
  • OFIX $21.80
  • AVG Volume (30 Days)
  • REPL 8.7M
  • OFIX 239.6K
  • Earning Date
  • REPL 11-07-2025
  • OFIX 11-04-2025
  • Dividend Yield
  • REPL N/A
  • OFIX N/A
  • EPS Growth
  • REPL N/A
  • OFIX N/A
  • EPS
  • REPL N/A
  • OFIX N/A
  • Revenue
  • REPL N/A
  • OFIX $809,030,000.00
  • Revenue This Year
  • REPL N/A
  • OFIX $3.88
  • Revenue Next Year
  • REPL N/A
  • OFIX $5.59
  • P/E Ratio
  • REPL N/A
  • OFIX N/A
  • Revenue Growth
  • REPL N/A
  • OFIX 4.84
  • 52 Week Low
  • REPL $2.68
  • OFIX $10.24
  • 52 Week High
  • REPL $17.00
  • OFIX $20.73
  • Technical
  • Relative Strength Index (RSI)
  • REPL 76.27
  • OFIX 54.47
  • Support Level
  • REPL $7.69
  • OFIX $15.23
  • Resistance Level
  • REPL $10.85
  • OFIX $16.05
  • Average True Range (ATR)
  • REPL 0.70
  • OFIX 0.43
  • MACD
  • REPL 0.43
  • OFIX -0.01
  • Stochastic Oscillator
  • REPL 89.86
  • OFIX 52.27

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About OFIX Orthofix Medical Inc. (DE)

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Share on Social Networks: